Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20000082HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20007360HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20027601HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20027588HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20015105HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20019576HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20019577HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20030913HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS44013030HTLV-1ENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TCGA Plot Options
Drug Information
GeneFGFR3
DrugBank IDDB15149
Drug NameFutibatinib
Target IDBE0002133
UniProt IDP22607
Regulation Typeinhibitor
PubMed IDs32973082
CitationsSootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H: Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24.
GroupsApproved; Investigational
Direct Classification
SMILESCOC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2
Pathways
PharmGKBPA166293381
ChEMBLCHEMBL3701238